HYPOLIPIDEMIC EFFECT AND LESKOL TOLERANCE IN HYPERTENSIVE PATIENTS WITH HYPERCHOLESTEROLEMIA - RESULTS OF MULTICENTER TRIAL

Hypertensive patients with hyperlipidemia are at high risk to develop coronary heart disease (CHD). Chemotherapeutic correction of hyperlipi demia seems most reliable modality to prevent CHD. Hypolipidemic effec t and tolerance of leskol (fluvastatin) in dietotherapy-resistant hype rcholesterolemia were studied in 74 patients with essential hypertensi on treated with hypotensive drugs. The patients were included in a mul ticenter trial. A 12-week course reduced total cholesterol level under 6.2 mmol/l in 59% of the patients, under 5.2 mmol/l in 29% of them. L DLP cholesterol lowered to 3.5% in 34% of the patients. Mean apo B dim inished by 23%. There was a 27% decrease in the proportion of atheroge nic fraction apo B to antiatherogenic fraction to transport proteins a po A-I. Leskol is well tolerated and effective against hypercholestero lemia, it is safe in relation to side effects and blood biochemistry.